Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:DSCI

Derma Sciences (DSCI) Stock Price, News & Analysis

Derma Sciences logo

About Derma Sciences Stock (NASDAQ:DSCI)

Advanced Chart

Key Stats

Today's Range
$7.00
$7.00
50-Day Range
N/A
52-Week Range
$2.92
$7.05
Volume
N/A
Average Volume
719,592 shs
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Derma Sciences, Inc. (Derma Sciences) is a medical device company. The Company operates through two segments: advanced wound care and traditional wound care products. Advanced wound care products principally consist of both novel and otherwise differentiated dressings, devices and skin substitutes designed to promote wound healing and/or prevent infection. The Company's advanced wound care product line consists of MEDIHONEY, TCC-EZ, AMNIOEXCEL and AMNIOMATRIX, XTRASORB and BIOGUARD. Traditional wound care products principally consist of commodity related dressings, ointments, gauze bandages, adhesive bandages, wound closure strips, catheter fasteners and skin care products. The Company's traditional wound care product line includes branded gauze sponges and bandages, non-adherent impregnated dressings, retention devices, paste bandages and other compression devices for the medical markets.

Receive DSCI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Derma Sciences and its competitors with MarketBeat's FREE daily newsletter.

DSCI Stock News Headlines

Roivant Sciences Acquires Dermavant, Expanding Dermatology Portfolio
Dermavant Sciences Ltd.
From Social Security to Social Prosperity?
In less than a decade, Social Security could be out of money. But a surprising plan from Trump’s inner circle may not just save the system — it could unlock a major opportunity for savvy investors. Financial insider Jim Rickards calls it “Social Prosperity,” and says those who act now could see the biggest gains.
See More Headlines

DSCI Stock Analysis - Frequently Asked Questions

Derma Sciences Inc (NASDAQ:DSCI) announced its earnings results on Tuesday, August, 9th. The medical instruments supplier reported $0.08 earnings per share for the quarter, beating the consensus estimate of ($0.08) by $0.16. The medical instruments supplier had revenue of $22.20 million for the quarter, compared to the consensus estimate of $22.40 million.

Based on aggregate information from My MarketBeat watchlists, some other companies that Derma Sciences investors own include Novavax (NVAX), Progenics Pharmaceuticals (PGNX), Palatin Technologies (PTN), Viking Therapeutics (VKTX), Allena Pharmaceuticals (ALNA), Antares Pharma (ATRS) and Bellicum Pharmaceuticals (BLCM).

Company Calendar

Last Earnings
8/09/2016
Today
4/27/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
N/A
Industry
N/A
Sub-Industry
Health Care Supplies
Current Symbol
NASDAQ:DSCI
Fax
N/A
Employees
N/A
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Price / Cash Flow
N/A
Price / Book
N/A

Miscellaneous

Free Float
N/A
Optionable
Not Optionable
Beta
N/A
5G Stocks: The Path Forward is Profitable Cover

Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

This page (NASDAQ:DSCI) was last updated on 4/28/2025 by MarketBeat.com Staff
From Our Partners